These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 31951091

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
    Puig C, Tirado-Vélez JM, Calatayud L, Tubau F, Garmendia J, Ardanuy C, Marti S, de la Campa AG, Liñares J.
    Antimicrob Agents Chemother; 2015 Jan; 59(1):461-6. PubMed ID: 25385097
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. GyrA and/or ParC alterations of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis.
    Kondo H, Ito S, Hatazaki K, Horie K, Nakane K, Mizutani K, Tsuchiya T, Yasuda M, Yokoi S, Nakano M, Deguchi T.
    J Infect Chemother; 2018 Mar; 24(3):232-235. PubMed ID: 29138021
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.
    Pérez-Vázquez M, Román F, Aracil B, Cantón R, Campos J.
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3539-41. PubMed ID: 14576114
    [Abstract] [Full Text] [Related]

  • 6. Microbial virulence, molecular epidemiology and pathogenic factors of fluoroquinolone-resistant Haemophilus influenzae infections in Guangzhou, China.
    Chen D, Wen S, Feng D, Xu R, Liu J, Peters BM, Su D, Lin Y, Yang L, Xu Z, Shirtliff ME.
    Ann Clin Microbiol Antimicrob; 2018 Nov 23; 17(1):41. PubMed ID: 30470228
    [Abstract] [Full Text] [Related]

  • 7. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
    Yokoi S, Yasuda M, Ito S, Takahashi Y, Ishihara S, Deguchi T, Maeda S, Kubota Y, Tamaki M, Fukushi H.
    J Infect Chemother; 2004 Oct 23; 10(5):262-7. PubMed ID: 16163459
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In Vitro Derivation of Fluoroquinolone-Resistant Mutants from Multiple Lineages of Haemophilus influenzae and Identification of Mutations Associated with Fluoroquinolone Resistance.
    Honda H, Sato T, Shinagawa M, Fukushima Y, Nakajima C, Suzuki Y, Kuronuma K, Takahashi S, Takahashi H, Yokota SI.
    Antimicrob Agents Chemother; 2020 Jan 27; 64(2):. PubMed ID: 31740553
    [Abstract] [Full Text] [Related]

  • 11. In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC.
    Yoshizumi S, Takahashi Y, Watanabe Y, Okezaki E, Ishii Y, Tateda K.
    Chemotherapy; 2004 Dec 27; 50(6):265-75. PubMed ID: 15608441
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ, Cho JK, Kim KS, Tak RB, Kim AR, Kim JW, Im SK, Kim BH.
    J Microbiol; 2005 Oct 27; 43(5):391-7. PubMed ID: 16273029
    [Abstract] [Full Text] [Related]

  • 16. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
    Shigemura K, Shirakawa T, Okada H, Hinata N, Acharya B, Kinoshita S, Kofuku T, Kawabata M, Kamidono S, Arakawa S, Gotoh A.
    Sex Transm Dis; 2004 Mar 27; 31(3):180-4. PubMed ID: 15076932
    [Abstract] [Full Text] [Related]

  • 17. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ.
    Antimicrob Agents Chemother; 2004 Oct 27; 48(10):3954-8. PubMed ID: 15388458
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
    Patel SN, Melano R, McGeer A, Green K, Low DE.
    Ann Clin Microbiol Antimicrob; 2010 Jan 18; 9():3. PubMed ID: 20082699
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N, Davies TA, Goldschmidt R.
    Antimicrob Agents Chemother; 2005 Jun 18; 49(6):2479-86. PubMed ID: 15917550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.